Skip to main content

Table 3 Multivariate analysis of predictions of overall survival of men with metastatic castration-resistant prostate cancer treated with cabazitaxel

From: Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel

  HR 95% CI P value
Lower Upper
Age (≥71.2 years vs < 71.2) 3.4 1.3 9.1 0.013
Number of cycles of docetaxel (≥10 cycles vs ≤9) 0.8 0.3 2.8 0.781
Baseline aBSI (≥1.0% vs < 1.0) 5.8 1.1 30.3 0.031
Baseline PSA (≥152.1 ng/mL vs < 152.1) 0.8 0.2 2.9 0.769
Baseline Hb (<  11.0 g/dL vs ≥11.0) 2.6 1.1 6.2 0.034
Baseline LDH (≥262 IU/L vs < 262) 3.3 1.3 8.6 0.014
Baseline ALP (≥414 IU/L vs < 414) 0.5 0.2 1.6 0.255
  1. aBSI automated bone scan index, ALP alkaline phosphatase, Hb hemoglobin, LDH lactate dehydrogenase, PSA prostate-specific antigen